Vanda Pharmaceuticals (VNDA)

$8.91 +0.31 (3.60%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	526.65M
Revenue (ttm)	216.11M
Net Income (ttm)	-220.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.02%
Debt to Equity Ratio	0.00

Volume	2,616,000
Avg Vol	3,130,326
Day's Range	N/A - N/A
Shares Out	59.11M
Stochastic %K	95%
Beta	0.62
Analysts	Strong Sell
Price Target	$14.88

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 734 3400

Fax: 202 296 1450

Website: www.vandapharma.com

Address:

2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States